Association Between Age at Diabetes Onset and Subsequent Risk of Dementia.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
27 04 2021
Historique:
entrez: 27 4 2021
pubmed: 28 4 2021
medline: 7 5 2021
Statut: ppublish

Résumé

Trends in type 2 diabetes show an increase in prevalence along with younger age of onset. While vascular complications of early-onset type 2 diabetes are known, the associations with dementia remains unclear. To determine whether younger age at diabetes onset is more strongly associated with incidence of dementia. Population-based study in the UK, the Whitehall II prospective cohort study, established in 1985-1988, with clinical examinations in 1991-1993, 1997-1999, 2002-2004, 2007-2009, 2012-2013, and 2015-2016, and linkage to electronic health records until March 2019. The date of final follow-up was March 31, 2019. Type 2 diabetes, defined as a fasting blood glucose level greater than or equal to 126 mg/dL at clinical examination, physician-diagnosed type 2 diabetes, use of diabetes medication, or hospital record of diabetes between 1985 and 2019. Incident dementia ascertained through linkage to electronic health records. Among 10 095 participants (67.3% men; aged 35-55 years in 1985-1988), a total of 1710 cases of diabetes and 639 cases of dementia were recorded over a median follow-up of 31.7 years. Dementia rates per 1000 person-years were 8.9 in participants without diabetes at age 70 years, and rates were 10.0 per 1000 person-years for participants with diabetes onset up to 5 years earlier, 13.0 for 6 to 10 years earlier, and 18.3 for more than 10 years earlier. In multivariable-adjusted analyses, compared with participants without diabetes at age 70, the hazard ratio (HR) of dementia in participants with diabetes onset more than 10 years earlier was 2.12 (95% CI, 1.50-3.00), 1.49 (95% CI, 0.95-2.32) for diabetes onset 6 to 10 years earlier, and 1.11 (95% CI, 0.70-1.76) for diabetes onset 5 years earlier or less; linear trend test (P < .001) indicated a graded association between age at onset of type 2 diabetes and dementia. At age 70, every 5-year younger age at onset of type 2 diabetes was significantly associated with an HR of dementia of 1.24 (95% CI, 1.06-1.46) in analyses adjusted for sociodemographic factors, health behaviors, and health-related measures. In this longitudinal cohort study with a median follow-up of 31.7 years, younger age at onset of diabetes was significantly associated with higher risk of subsequent dementia.

Identifiants

pubmed: 33904867
pii: 2779197
doi: 10.1001/jama.2021.4001
pmc: PMC8080220
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1640-1649

Subventions

Organisme : Medical Research Council
ID : MR/R024227/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG056477
Pays : United States
Organisme : Medical Research Council
ID : MR/S011676/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : RF1 AG062553
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Diabetes. 2009 Jan;58(1):71-7
pubmed: 18952836
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Expert Rev Clin Pharmacol. 2017 Apr;10(4):409-428
pubmed: 28276776
Lancet Neurol. 2020 Sep;19(9):758-766
pubmed: 32730766
Diabetes Care. 2019 Jul;42(7):1248-1254
pubmed: 31221696
N Engl J Med. 2013 Aug 8;369(6):540-8
pubmed: 23924004
Lancet. 2017 Jun 3;389(10085):2239-2251
pubmed: 28190580
Ann Fam Med. 2005 Jan-Feb;3(1):60-3
pubmed: 15671192
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
Diabetes Res Clin Pract. 2017 Feb;124:41-47
pubmed: 28088029
Alzheimers Dement. 2018 Jul;14(7):933-943
pubmed: 29703698
Nat Rev Neurol. 2018 Mar;14(3):168-181
pubmed: 29377010
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):7-14
pubmed: 31766915
Lancet Diabetes Endocrinol. 2020 Apr;8(4):325-336
pubmed: 32135131
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Intern Med J. 2012 May;42(5):484-91
pubmed: 22372522
Lancet Diabetes Endocrinol. 2016 Feb;4(2):115-24
pubmed: 26704379
Alzheimers Dement. 2018 Aug;14(8):1038-1051
pubmed: 29621480
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
JAMA Neurol. 2015 Sep;72(9):1013-20
pubmed: 26214150
Lancet Diabetes Endocrinol. 2020 Sep;8(9):736-738
pubmed: 32738930
Nat Rev Drug Discov. 2020 Sep;19(9):609-633
pubmed: 32709961
Ageing Res Rev. 2019 Nov;55:100944
pubmed: 31430566
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Lancet Diabetes Endocrinol. 2014 Mar;2(3):228-35
pubmed: 24622753
BMJ. 2019 Apr 17;365:l1495
pubmed: 30995986
Int J Epidemiol. 2013 Aug;42(4):1012-4
pubmed: 24062287
Circulation. 2019 May 7;139(19):2228-2237
pubmed: 30955347
BMJ Open Diabetes Res Care. 2018 Nov 16;6(1):e000563
pubmed: 30487973
Lancet. 1991 Jun 8;337(8754):1387-93
pubmed: 1674771
Diabetes Care. 2016 Feb;39(2):300-7
pubmed: 26681727
Lancet. 2009 Jun 27;373(9682):2215-21
pubmed: 19515410
Diabetes Care. 2003 Mar;26(3):725-31
pubmed: 12610029
JAMA Intern Med. 2013 Jul 22;173(14):1300-6
pubmed: 23753199
Epidemiology. 2014 Nov;25(6):932-3
pubmed: 25265141
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
Alzheimers Dement. 2020 Feb;16(2):316-325
pubmed: 31718906
Ann Intern Med. 2014 Dec 2;161(11):785-93
pubmed: 25437406

Auteurs

Claudio Barbiellini Amidei (C)

Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Inserm U1153, Paris, France.
Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Aurore Fayosse (A)

Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Inserm U1153, Paris, France.

Julien Dumurgier (J)

Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Inserm U1153, Paris, France.
Cognitive Neurology Center, Lariboisière - Fernand Widal Hospital, AP-HP, Université de Paris, Paris, France.

Marcos D Machado-Fragua (MD)

Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Inserm U1153, Paris, France.

Adam G Tabak (AG)

Department of Epidemiology and Public Health, University College London, United Kingdom.
Department of Internal Medicine and Oncology, Semmelweis University Faculty of Medicine, Budapest, Hungary.
Department of Public Health, Semmelweis University Faculty of Medicine, Budapest, Hungary.

Thomas van Sloten (T)

Cardiovascular Research Institute Maastricht (CARIM), Department of Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.

Mika Kivimäki (M)

Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Department of Epidemiology and Public Health, University College London, United Kingdom.

Aline Dugravot (A)

Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Inserm U1153, Paris, France.

Séverine Sabia (S)

Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Inserm U1153, Paris, France.
Department of Epidemiology and Public Health, University College London, United Kingdom.

Archana Singh-Manoux (A)

Epidemiology of Ageing and Neurodegenerative Diseases, Université de Paris, Inserm U1153, Paris, France.
Department of Epidemiology and Public Health, University College London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH